Amgen seeks to expand denosumab indication to include myeloma

Amgen has announced it has submitted respective applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to expand the currently approved indication for denosumab (Xgeva®) to include myeloma patients. At present, denosumab is licensed for the prevention of skeletal-related events (SREs) in solid cancer patients but results from a recent…

Details